Latest California Healthline Stories
As fires burn longer and closer to cities throughout the West, researchers are trying to understand the lasting health impacts by studying a Montana town previously smothered by wildfire smoke.
Epidemiologists and disease modelers tried to predict what would happen when students moved back to campus. Although some universities listened to their advice, that didn’t stop outbreaks from happening.
Since the COVID-19 pandemic hit, more patients are administering dialysis to themselves at home rather than receiving it in a clinic. Although home dialysis limits exposure to the virus, it comes with its own challenges.
A KHN review found more than 20 states either don’t count or have incomplete data on the use of COVID-19 antigen tests, leaving the public in the dark about the true scope of the pandemic.
Midwifery was a tradition among slaves from Africa, but in more recent decades, pregnant Black women have generally shunned the approach. Now, home births and midwives are making a comeback in the Black community.
The National Institutes of Health has suggested minorities should be overrepresented in COVID-19 vaccine trials — perhaps at rates that are double their percentage of the U.S. population. But efforts to recruit patients from racial minority groups are just beginning, while some trials have already advanced to phase 3.
As people leave COVID-stricken cities to settle semi-permanently in vacation communities, locals assess how these new residents are changing demands on medical services.
A new treatment for tooth decay is cheaper, quicker and less painful than getting a filling. Originally touted as a solution for kids, silver diamine fluoride is poised to become a game changer for treating cavities in older adults or those with disabilities that make oral care difficult.
Respiratory symptoms stemming from coronavirus infection and smoke inhalation are too similar to distinguish without a full workup. This is complicating the jobs of health care workers as wildfires rage up and down the West Coast.
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.